Daily Respiratory Research Analysis
Analyzed 141 papers and selected 3 impactful papers.
Summary
A large cluster randomized trial in rural China showed a comprehensive, digitally enabled antibiotic stewardship program cut antibiotic prescribing for acute respiratory infections by 39 percentage points without safety trade-offs. Translational immunology advanced on two fronts: a monoclonal antibody cocktail derived from pediatricians’ occupational exposure provided cross-protection against RSV and hMPV in animals, and a meta-analysis found strong real-world effectiveness of newly introduced RSV vaccines in older adults.
Research Themes
- Antimicrobial stewardship to reduce inappropriate antibiotics in respiratory infections
- Cross-viral monoclonal antibody prophylaxis (RSV and hMPV)
- Real-world vaccine effectiveness in older adults
Selected Articles
1. Effects of a comprehensive antibiotic stewardship program on antibiotic prescribing for acute respiratory infections in rural facilities: a cluster randomized trial.
In a 34-cluster pragmatic RCT across rural China, a multifaceted, digitally enabled stewardship package reduced antibiotic prescribing for ARIs by 39 percentage points without increasing 30-day respiratory/sepsis hospitalizations. Embedding concise, evidence-based prompts in EMRs, peer feedback, and patient education proved scalable and safe.
Impact: Demonstrates at scale that digital, team-based stewardship can dramatically reduce inappropriate antibiotics for ARIs, a key driver of antimicrobial resistance, with immediate policy relevance.
Clinical Implications: Primary care systems can implement integrated digital decision support, audit-feedback, and patient education to curb ARI antibiotic overuse without compromising safety; payers and ministries can scale similar packages.
Key Findings
- Antibiotic prescribing for ARIs fell from 71% to 26% with the stewardship program (adjusted risk difference −39 percentage points).
- No increase in 30-day hospitalizations for respiratory illness or sepsis (adjusted risk difference 0.2 percentage points).
- Intervention components included EMR-embedded prompts, clinician training, peer review feedback, and a patient education app.
Methodological Strengths
- Pragmatic cluster randomized design across 34 hospitals with 97,239 consultations.
- Pre-specified primary outcome and safety endpoints; large effect size with narrow CIs.
Limitations
- Open-label design with potential contamination between clusters.
- Conducted during 2020–2021, when pandemic dynamics may have influenced ARI presentations and care-seeking.
Future Directions: Assess durability and cost-effectiveness over multiple seasons and regions, optimize component-level contributions, and evaluate adaptation to different EMR ecosystems.
Antimicrobial resistance is driven by inappropriate use of antibiotics for acute respiratory infections (ARIs), which is a major challenge in primary care in low- and middle-income countries. Here we conducted a pragmatic, cluster randomized controlled trial in 34 township hospitals in two rural counties of Guangdong, China, to evaluate whether a digitally enabled stewardship program could reduce antibiotic prescribing. The intervention combined training and guidelines for doctors; concise, evidence-based guidelines embedded in the electronic medical record with point-of-care prompts; monthly prescribing peer review feedback for doctors; and patient education delivered through a smartphone app. Control is usual care with no inputs. During the 12-month implementation period (1 March 2020 to 28 February 2021), we analyzed 97,239 eligible consultations for ARIs. The primary outcome was whether a consultation resulted in any antibiotics being prescribed. This outcome was met: antibiotics were prescribed in 26% (14,521/54,799) of intervention consultations compared to 71% (30,340/42,440) of control consultations, yielding an adjusted risk difference of -39 percentage points (95% confidence interval: -47 to -29; P < 0.001). There was no evidence of increased harm, as 30-day hospitalization rates for respiratory illness or sepsis did not differ between groups (adjusted risk difference, 0.2 percentage points; 95% confidence interval: -0.3 to 0.6). A comprehensive stewardship program can substantially reduce inappropriate antibiotic prescribing for ARIs in rural primary care facilities in China without compromising patient safety. Trial registration: ISRCTN96892547 .
2. Antibody cocktails based on the occupationally acquired immunity of pediatricians neutralize and confer protection against RSV and hMPV.
Three human mAbs isolated from frequently exposed pediatricians potently neutralized RSV (CNR2056/2053) and cross-neutralized hMPV (CNR2047), providing in vivo prophylactic protection in cotton rats and mice. Structural mapping and deep mutational scanning indicate escape would require fitness-costly mutations, supporting rational cocktails (e.g., site Ø + site III) to broaden coverage and limit resistance.
Impact: Introduces a rational, cross-viral monoclonal antibody cocktail strategy with in vivo efficacy against RSV and hMPV, addressing a major unmet need in immunoprophylaxis for vulnerable populations.
Clinical Implications: Provides a blueprint for antibody combinations targeting conserved F protein epitopes to extend prophylaxis beyond RSV to hMPV, with potential resilience to escape; informs next-generation passive immunization strategies.
Key Findings
- Site Ø-directed mAbs (CNR2056, CNR2053) potently neutralized diverse RSV A/B strains; site III mAb (CNR2047) cross-neutralized RSV and hMPV.
- Prophylactic dosing controlled lung viral load/pathology in RSV-challenged cotton rats and completely protected BALB/c mouse lungs from hMPV at 0.5 mg/kg.
- Deep mutational scanning showed escape mutations cluster in constrained residues, implying fitness costs; combining site Ø + site III mAbs broadened coverage and minimized escape.
Methodological Strengths
- Integrated structural biology, deep mutational scanning, and in vivo challenge models.
- Use of human mAbs derived from naturally exposed donors enhances translational relevance.
Limitations
- Preclinical evidence; no human pharmacokinetic or efficacy data.
- Donor diversity and breadth of viral variants tested were limited relative to global circulation.
Future Directions: Advance to phase 1 safety/PK trials, assess breadth against emerging pneumovirus variants, and optimize dosing/combination ratios for long-acting prophylaxis.
Human respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) are major causes of severe respiratory infections in young children, older adults, and immunocompromised individuals. Here, we isolated RSV fusion (F) protein-specific B cells from pediatricians who are routinely exposed to these viruses. We then derived monoclonal antibodies (mAbs) from those B cells to characterize their binding and neutralization profiles. Among the isolated mAbs, we found that CNR2056 and CNR2053 (targeting site Ø of the pre-F protein) potently neutralized diverse RSV A and B strains; another mAb, CNR2047 (targeting site III), uniquely exhibited cross-neutralization capacity against both RSV and hMPV variants. In vivo, prophylactic administration of CNR2056 and CNR2053 controlled lung viral loads and pathology in RSV A2- and B9320-challenged cotton rats. Moreover, a prophylactic dose of 0.5 milligrams per kilogram of CNR2047 resulted in complete protection against hMPV in the lungs of BALB/c mice. Structural analysis revealed unique binding modes for the three mAbs, supporting the potential for rational mAb cocktail design. Deep mutational scanning for RSV F further demonstrated that mutations required to evade CNR2053 and CNR2056 were primarily in evolutionarily constrained sites, suggesting a fitness cost to immune escape. Rationally combining site Ø- and site III-directed mAbs (e.g., CNR2056-CNR2047) into cocktails conferred additive effects, expanding coverage to hMPV and minimizing risk of escape variants. Thus, rationally designed cocktails of CNR2056, CNR2053, and CNR2047 may offer a versatile immunoprophylactic agent against a range of pneumoviruses with potential to protect against both current and future variants.
3. Real-World Effectiveness of RSVpreF and RSVpreF3 Vaccines in Preventing Hospitalisation and Emergency Department Visits Associated with Respiratory Syncytial Virus in Older Adults: A Meta-Analysis.
Across eight real-world observational studies, RSVpreF and RSVpreF3 vaccination reduced RSV-related hospitalizations and ED visits in older adults by about 77% (OR ≈0.23), with slightly lower effectiveness in immunocompromised individuals. Protection was consistent across ages 60–74 vs ≥75 and between vaccine products.
Impact: Provides timely, policy-relevant real-world effectiveness estimates for newly introduced RSV vaccines in older adults, complementing trial data and informing program implementation.
Clinical Implications: Supports broad deployment of RSV vaccination in older adults, with consideration for tailored strategies to enhance protection in immunocompromised populations.
Key Findings
- Pooled OR for RSV-related hospitalization was 0.23 (95% CI 0.20–0.27; I²=6.5%), and for ED visits 0.23 (95% CI 0.21–0.27; I²=0.0%).
- Effectiveness was lower but still substantial in immunocompromised adults (hospitalization OR 0.31) versus immunocompetent (OR 0.20).
- No significant differences in effectiveness by age group (60–74 vs ≥75) or by vaccine product (RSVpreF vs RSVpreF3).
Methodological Strengths
- Systematic search across multiple databases with PROSPERO registration.
- Low heterogeneity and consistent findings across included observational designs.
Limitations
- All included studies were observational, with potential residual confounding.
- Early post-licensure period; durability and season-to-season variation remain to be defined.
Future Directions: Evaluate durability across seasons, effectiveness against severe endpoints and in high-risk subgroups, and combined strategies (e.g., vaccination plus monoclonal antibodies).
BACKGROUND: Respiratory syncytial virus (RSV) vaccines were first recommended for older adults during the 2023-24 season in countries that authorised their use. Although early observational studies complemented trial findings, real-world evidence on vaccine effectiveness against severe RSV disease remains limited. We assessed the effectiveness of RSVpreF and RSVpreF3 vaccines in preventing RSV-related hospitalisations and emergency department (ED) visits among older adults. METHODS: We searched MEDLINE, Embase, Web of Science, Scopus, Global Health, and medRxiv for observational studies published between January 1, 2023 and December 30, 2025, reporting real-world effectiveness of RSV vaccines in adults aged 60 years or older. Pooled analyses used inverse-variance random-effects models to estimate effectiveness against RSV-related hospitalisations and ED visits. Subgroup analyses assessed differences in effectiveness by age, immune status, and vaccine type. This study is registered with PROSPERO (CRD420251021777). RESULTS: From 4925 records screened, 8 cohort and case-control studies were included. Vaccination was associated with lower odds of RSV-related hospitalisation (odds ratio [OR]: 0.23; 95% Confidence Interval [CI]: 0.20-0.27; I²=6.5%) and ED visits (OR: 0.23; 95% CI: 0.21-0.27; I²=0.0%). Effectiveness against RSV-related hospitalisation was lower in immunocompromised adults (OR: 0.31; 95% CI: 0.27-0.34; I²=0.0%) than in immunocompetent individuals (OR: 0.20; 95% CI: 0.11-0.35; I²=0.0%). Effectiveness did not differ by age group (60-74 vs ≥75 years) or vaccine product. CONCLUSIONS: Vaccination provided substantial protection against RSV-related healthcare utilisation among older adults. Continued surveillance and real-world evidence are needed to inform immunisation policy and improve protection in immunocompromised individuals.